Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your Number one Sort Of Music - 2Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- 3Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- 4Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- 5Scientists may be overestimating the amount of microplastics in the environment – and the culprit is lab gloves
- 6 Asian Urban areas to Visit
- What are the health benefits of whole milk for kids?
- The Oscars are moving from ABC to YouTube starting in 2029
- Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
- Former Israeli judge does not expect Netanyahu to be pardoned
- Careful Living: Embracing the Current Second
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
